Please sign in to follow a disease.
Movement disorder
MONDO:0005395Neurological conditions resulting in abnormal voluntary or involuntary movement, which may impact the speed, fluency, quality and ease of movement.
Also known as: movement disease, movement disorder, movement disorders
697 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Continued EryDex treatment studied in rare neurological disorder
Disease control TerminatedThis study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (A-T) who had finished a previous trial. The main goal was to monitor safety, including side effects and serious events. The study was terminated early, and it did not aim to cure the dise…
Phase: PHASE3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental drug shows promise for rare genetic disorder
Disease control TerminatedThis Phase II trial tested a drug called N-Acetyl-L-Leucine (IB1001) in 17 people with Ataxia-Telangiectasia, a rare genetic disease that affects movement and immunity. The study aimed to see if the drug could improve symptoms and slow the disease over time. The trial was termina…
Phase: PHASE2 • Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Virus therapy fails to advance in colorectal cancer trial
Disease control TerminatedThis study tested a new approach using a virus that attacks cancer cells (oncolytic immunotherapy) along with two standard drugs (atezolizumab and bevacizumab) in people with advanced colorectal cancer that had stopped responding to other treatments. The trial was stopped early a…
Phase: PHASE2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental Friedreich's ataxia drug tested in kids – but trial halted early
Disease control TerminatedThis early-stage trial tested a drug called nomlabofusp (CTI-1601) in 18 adolescents and children with Friedreich's ataxia, a rare genetic disease that affects movement and coordination. The goal was to check safety and how the body processes the drug. However, the study was term…
Phase: PHASE1 • Sponsor: Larimar Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Huntington's drug safety study halted early
Disease control TerminatedThis study aimed to see if the drug SAGE-718 is safe for people with Huntington's disease when taken over a long period. It was an open-label study, meaning everyone knew they were getting the drug. The study was terminated early, so results are limited.
Phase: PHASE3 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Experimental cell therapy targets deadly childhood brain cancer
Disease control TerminatedThis early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 particip…
Phase: PHASE1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New radiation technique aims to calm tremors without surgery
Symptom relief TerminatedThis study tested a new way to treat hand tremors caused by essential tremor or Parkinson's disease using a linear accelerator, a common radiation machine. Instead of one large dose, the radiation was given in three smaller sessions to protect healthy brain tissue. The goal was t…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Experimental drug aims to curb disinhibition in dementia patients
Symptom relief TerminatedThis study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated ear…
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Brain pacemaker tested for uncontrollable tics
Symptom relief TerminatedThis study tested whether deep brain stimulation (DBS) could help people with severe Tourette syndrome whose symptoms don't improve with medication. Researchers placed tiny electrodes in a part of the brain called the thalamus to try to calm abnormal signals that cause tics. Only…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Scientists probe Brain's consciousness switch during anesthesia
Knowledge-focused TerminatedThis study looked at how anesthesia changes brain activity in people with Parkinson's disease or essential tremor who were already scheduled for deep brain stimulation (DBS) surgery. Researchers recorded brain signals during a short period of anesthesia to understand which circui…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Scientists probe hidden danger of low blood sugar in diabetes
Knowledge-focused TerminatedThis study looked at why people with type 1 diabetes often fail to sense dangerously low blood sugar (hypoglycemia). Researchers tested how opioid drugs like morphine and naloxone affect the body's ability to respond to low sugar. The goal was to better understand the problem, no…
Phase: PHASE2 • Sponsor: Albert Einstein College of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
3D scans reveal hidden Muscle's role in twisted neck disorder
Knowledge-focused TerminatedThis study looked at how a small neck muscle called the obliquus capitis inferior (OCI) contributes to abnormal head rotation in cervical dystonia. Researchers used 3D CT scans to measure muscle function before and after botulinum toxin injections in 21 adults. The goal was to be…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC